SAN FRANCISCO (

TheStreet

) --Welcome to the J.P. Morgan Biotech Confab Live Chat.

I'm here to offer my take on the first day of the biotech sector's largest and most important investor conference. And of course, I'm happy to answer your biotech stock investing questions.

This year's J.P. Morgan conference should be renamed the Hepatitis C Hoedown for the buzz being generated about

Bristol-Myers Squibb's

(BMY) - Get Report

$2.5 billion acquisition of

Inhibitex

( INHX) and the resulting speculative mania that is gripping

Idenix Pharmaceuticals

(IDIX)

and

Achillion Pharmaceuticals

(ACHN) - Get Report

. Both stocks are seen as potential takeover targets, too, but how likely is that or is it just wishful thinking?

I spent my day listening to presentations by

Celgene

(CELG) - Get Report

,

Onyx Pharmaceuticals

(ONXX)

,

Amarin

(AMRN) - Get Report

,

Vivus,

(VVUS) - Get Report

and

Dendreon

(DNDN)

.

--Written by Adam Feuerstein in San Francisco.

>To contact the writer of this article, click here:

Adam Feuerstein

.

>To follow the writer on Twitter, go to

http://twitter.com/adamfeuerstein

.

>To submit a news tip, send an email to:

tips@thestreet.com

.

Follow

TheStreet

on

Twitter

and become a fan on

Facebook.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;

click here

to send him an email.